A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate DS-6000a in participants with advanced renal cell carcinoma
(RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the
recommended dose of DS-6000a that can be given safely to participants, assess the side
effects of DS-6000a, and evaluate the effectiveness of DS-6000a.